PLOS: DNA Science

SEPTEMBER 5, 2024

Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015. This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

The Pharma Data

APRIL 22, 2023

These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

MARCH 8, 2022

Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice. Also, the incidence of severe disease progression was observed to be significantly reduced.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

APRIL 20, 2023

There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment. New therapeutics of course depend on an understanding of biological mechanisms.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. Though more study is needed, the researchers say the decoy therapy could potentially be delivered directly to the lungs through an inhaler and used alone or in combination with other COVID-19 treatments.

Virus 52

Virus Clinical Trials Engineering Immune Response 52

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Testing Therapies, Antivirals and Vaccines. Eli Lilly halted a separate study of its LY-COV555 antibody against COVID-19 in hospitalized patients.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 12, 2020

José Baselga, Executive Vice President, Oncology R&D, said: “Since the beginning of the year, AstraZeneca has been committed to doing everything we can to respond to COVID-19, including investigating existing medicines as potential treatments. CALAVI US). NCT identifier: NCT04380688. Available online. Accessed October 2020.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

OCTOBER 16, 2020

COVID-19 Antibody Treatment Study Paused. 14, 2020 — Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors. Immune Responses Long-Lasting After Serious COVID-19. THURSDAY, Oct. 12 in JAMA Pediatrics. Read Full Article. WEDNESDAY, Oct. WEDNESDAY, Oct.

Hospitals 52

Hospitals Immune Response Vaccine Trials 52

Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Medical Schools 128

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

FEBRUARY 18, 2022

“For clinicians treating patients with this serious, chronic disease, results from the True North extension study provide an understanding of long-term therapeutic outcomes and help to identify an appropriate treatment approach for their patients with ulcerative colitis,” said Silvio Danese, M.D., About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Immune Response Treatment Disease 40

Drug Discovery World

MARCH 13, 2023

GenSight Biologics has revealed pooled safety data from five clinical studies of lenadogene nolparvovec (Lumevoq), the largest cohort of ND4-LHON (Leber hereditary optic neuropathy) patients studied after gene therapy treatment. The post Five-year data show gene therapy safe for ND4-LHON appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Immune Response Hospitals Treatment 130

The Pharma Data

NOVEMBER 19, 2020

The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. The study evaluated 546 healthcare works with direct patient exposure at two hospitals in New Jersey and 283 non-healthcare workers that did not have direct patient contact. Source link.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. I-SPY COVID-19 is assessing multiple drugs for critical COVID-19 hospitalized or ICU patients. Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 10, 2020

We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 118

Therapies Virus DNA Clinical Trials 118

The Pharma Data

NOVEMBER 1, 2020

In view of the importance and urgency, scientific teams at the Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) and at Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames. NEW YORK and LONDON, Nov. Dr Howard Weiner, who is the Robert L.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania.

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). Clinical results in the overall population (n=799): On the key clinical endpoint, treatment with REGN-COV2 reduced COVID-19 related medical visits by 57% through day 29 (2.8%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. 1 Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Drug Discovery World

AUGUST 2, 2023

PPT1 inhibitors for the treatment of patients with cancer Contemplating the potential of PPT1 inhibition in cancer led to the development of small molecules with high PPT1 affinity and limited toxicity for clinical drug development. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

The Pharma Data

NOVEMBER 20, 2020

(NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Schleifer, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

OCTOBER 14, 2020

These dual constructs (bivalent sequences) of SARS-CoV-2 offer the potential for the hAd5 vaccine to provide recipients with durable, long-term cell-mediated immunity with potent antibody stimulation against both the S and N proteins. based Hoag Hospital this month with adult subjects up to age 55. Forward-Looking Statements.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

Antiviral therapies are used to help control disease, but they are limited by toxicity and the emergence of viral resistance. Participants receive either pre-emptive or prophylactic antiviral therapy post-transplant and are followed for a 12-month observation period. About HOOKIPA HOOKIPA Pharma Inc.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

Drug Discovery World

NOVEMBER 8, 2023

On Day 1, Tuesday 14 November 2023, the tracks include: Display of biologics, antibody-based cancer therapies, safety and efficacy of bispecific antibodies, modulating the tumour microenvironment, optimisation and developability, and cell line and systems engineering. from engineered peptide and antibody libraries’.

Engineering 162

Engineering Protein Expression Therapies Science 162

Codon

JULY 14, 2024

The transfusion of platelets thus seems like an obvious treatment to stem bleeding. From Early Transfusion to Component Therapy The earliest documented attempts at blood transfusions involved the transfer of blood from animals to humans in the 17 th century. Component therapy offers several advantages over whole blood.

Production 133

Production Clinical Trials Trials Therapies 133

The Pharma Data

APRIL 16, 2021

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib. professor of medicine and urology department head, Jena University Hospital.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Ultimately, such approaches lead to personalised treatment.

Bioinformatics 130

Bioinformatics RNA Vaccine Clinical Trials 130